Managing Choroidal Neovascularization in Pseudoxanthoma Elasticum: Outcomes of Vitrectomy and Intravitreal Ranibizumab/Aflibercept Therapy-A Case Report

假性黄瘤合并脉络膜新生血管的治疗:玻璃体切除术联合玻璃体内注射雷珠单抗/阿柏西普治疗的疗效——病例报告

阅读:1

Abstract

Background: Pseudoxanthoma elasticum (PXE) is a systemic disorder that affects the skin, eyes, and vascular system. It commonly presents with retinal angioid streaks (ASs) and can lead to vision loss due to subretinal neovascularizations and macular atrophy. Diagnosis is confirmed through skin biopsies showing calcified elastic fibers or identifying biallelic ABCC6 pathogenic variants. This case report is novel as it describes the clinical course of choroidal neovascularization (CNV) secondary to PXE treated with vitrectomy and intravitreal ranibizumab and aflibercept injections in both eyes. Case Presentation: A 68-year-old woman presented with vision loss in her right eye. Her medical history included hypertension, uterine fibroids, and multiple drug allergies. Ophthalmic examination revealed radial AS around the optic discs and subretinal hemorrhages in the right eye. Fluorescein angiography and optical coherence tomography confirmed CNV and fresh subretinal hemorrhage. A series of vitrectomies and intravitreal injections of ranibizumab and aflibercept were performed to manage the CNV and submacular hemorrhage. Despite recurrence, subsequent surgeries stabilized her condition, improving her best-corrected visual acuity to 20/125 in the right eye over 6 years. A skin biopsy confirmed the diagnosis of PXE, a condition she had overlooked for over 30 years. Conclusions: This case emphasizes the importance of early detection of AS through thorough fundus examination, alongside comprehensive evaluation for systemic conditions. Management of CNV in PXE involves the prompt use of intravitreal anti-VEGF injections and vitrectomy with tissue plasminogen activator (tPA) for controlling CNV activity and submacular hemorrhage. Ophthalmologists should consider PXE in patients presenting with characteristic skin and eye findings and refer them for dermatological evaluation as necessary.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。